Purpose: To evaluate progression pattern and progression-free interval for patients with glioblastoma multiforme (GBM), on the basis of the extent of resection.
Materials And Methods: Between January 2000 and September 2009, 138 patients with GBM underwent postoperative radiation therapy and longitudinal magnetic resonance imaging studies. The operations were classified as biopsy, partial resection (PR), and gross total resection (GTR). Progression patterns were classified as gross tumor volume (GTV), T2 hyperintensity (T2h), distant, and free. We used the Kruskal-Wallis test to compare progression-free intervals on the basis of the extent of resection and the progression pattern.
Results: Recurrence of biopsied and PR tumors at the GTV site was 100 and 97%, respectively. The median progression-free interval was 3 months for biopsied (n = 29), 4 months for PR (n = 70), and 8 months for GTR (n = 39) tumors (p < 0.05). The median progression-free interval for progression patterns classified as GTV (n = 97), T2h (n = 24), distant (n = 12), and free (n = 5) was 3 (p < 0.05), 7, 8, and 29 months, respectively.
Conclusion: Control of the GTV can increase the progression-free interval because gross residual tumors progress earlier than infiltrating tumor cells do.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11604-011-0031-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial.
Cancer Commun (Lond)
January 2025
Department of Medical Oncology, Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, P. R. China.
Background: The standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive recurrent/metastatic breast cancer currently includes pertuzumab plus trastuzumab and docetaxel. This study aimed to evaluate the effectiveness of KN026, an anti-HER2 bispecific antibody, plus docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer.
Methods: This open-label, single-arm, phase II study enrolled patients with HER2-positive recurrent/metastatic breast cancer in 19 centers across China from December 30, 2019 to May 27, 2021.
Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial.
Int J Cancer
January 2025
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
The effectiveness and safety of combining anlotinib with gemcitabine and cisplatin in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) have not been definitively established. This research seeks to investigate the potential benefits and risks of utilizing this combination therapy in the first-line management of R/M NPC. The research involved 22 individuals diagnosed with R/M NPC and who had not undergone any previous treatment.
View Article and Find Full Text PDFObjectives: To evaluate the benefit of neoadjuvant chemotherapy (NAC) for patients with high-risk upper tract urothelial carcinoma (UTUC) using a large, well-curated multi-institutional database.
Patients And Methods: This study was a multi-institutional retrospective analysis conducted by the UTUC Collaborative Network (UCAN), combining data from 2276 patients with UTUC who underwent radical nephroureterectomy at seven high-volume tertiary care centres in the United States. The UCAN data were analysed to evaluate the impact of response to NAC on survival outcomes in patients with UTUC.
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell growth and differentiation, and is overexpressed in several tumor types, including breast, gastric and colorectal cancer. HER2-targeted therapies have shown clinical activity against these tumor types, resulting in regulatory approvals. However, the efficacy of HER2 therapies in tumors with HER2 mutations has not been widely investigated.
View Article and Find Full Text PDFA systematic review and network meta-analysis of RCTs: The effect of systemic immunotherapies on treatment outcomes and quality of life in patients with metastatic colorectal cancer.
Adv Clin Exp Med
January 2025
Department of Clinical Laboratory, Shandong Provincial Third Hospital, Jinan, China.
Background: The impact of different systemic treatments on the health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) is still unclear.
Objectives: To compare and evaluate the effects of various systemic interventions on the HRQoL in patients with mCRC.
Material And Methods: A thorough search was conducted using four electronic databases (PubMed, Embase, Scopus, and Cochrane Library) to locate relevant literature published in peer-reviewed journals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!